FDA ORA RESPONSIBILITY FOR BIOLOGICS PRE-LICENSING INSPECTIONS BEING CONSIDERED; TEAM BIOLOGICS PLAN TRANSFERS LEAD ON POST-APPROVAL INSPECTIONS TO ORA
Executive Summary
FDA is testing whether giving the Office of Regulatory Affairs a lead role in pre-approval biologics inspections would have any adverse effects on user fee review times under the agency's "Team Biologics" initiative.